{"id":"ibi112","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IBI112 is a humanized monoclonal antibody targeting programmed death receptor 1 (PD-1). By blocking PD-1, the drug prevents tumor cells from suppressing T cell-mediated immunity, allowing the immune system to recognize and attack cancer cells more effectively. This mechanism is similar to other checkpoint inhibitors and is designed to enhance endogenous anti-tumor immunity across multiple cancer types.","oneSentence":"IBI112 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:18.584Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Gastric cancer"},{"name":"Other solid tumors (in development)"}]},"trialDetails":[{"nctId":"NCT07265284","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis","status":"RECRUITING","sponsor":"Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.","startDate":"2025-12-03","conditions":"Psoriasis","enrollment":104},{"nctId":"NCT05377580","phase":"PHASE2","title":"A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2022-07-01","conditions":"Ulcerative Colitis (UC)","enrollment":150},{"nctId":"NCT06049810","phase":"PHASE3","title":"IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2023-10-10","conditions":"Psoriasis","enrollment":566},{"nctId":"NCT05970978","phase":"PHASE2","title":"A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2023-08-28","conditions":"Psoriasis","enrollment":152},{"nctId":"NCT05645627","phase":"PHASE3","title":"A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2023-02-10","conditions":"Psoriasis","enrollment":500},{"nctId":"NCT05003531","phase":"PHASE2","title":"A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-09-23","conditions":"Psoriasis","enrollment":250},{"nctId":"NCT04511624","phase":"PHASE1","title":"Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2020-08-27","conditions":"Healthy Subjects","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"IBI112","genericName":"IBI112","companyName":"Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.","companyId":"innovent-biopharmaceutical-technology-hangzhou-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IBI112 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses. Used for Non-small cell lung cancer, Gastric cancer, Other solid tumors (in development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}